Skip to Content

Selzentry Approval History

  • FDA approved: Yes (First approved August 6th, 2007)
  • Brand name: Selzentry
  • Generic name: maraviroc
  • Company: ViiV Healthcare
  • Treatment for: HIV Infection

Selzentry (maraviroc) is the first in a class of drugs known as CCR5 antagonists, approved for use in combination with other antiretroviral drugs for the treatment of adults with CCR5-tropic HIV-1, who have been treated with other HIV medications and who have evidence of elevated levels of HIV in their blood (viral load).

Development History and FDA Approval Process for Selzentry

Aug  6, 2007Approval Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA
Jun 21, 2007Pfizer Receives Approvable Letter From FDA For Maraviroc
Apr 25, 2007FDA Advisory Committee Recommends Accelerated Approval of Pfizer’s Maraviroc for Treatment-Experienced Patients
Feb 13, 2007Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.